Medvi Review 2026: What You Should Know Before Signing Up
April 1, 2026
Medvi has been one of the fastest-growing telehealth companies in the United States, reportedly generating over $400 million in revenue in 2025 selling compounded GLP-1 weight loss medications. With aggressive advertising across Facebook, Instagram, and TikTok, they've attracted hundreds of thousands of customers looking for affordable alternatives to brand-name Ozempic and Wegovy.
But a series of investigations in 2025 and 2026 have raised serious questions about how Medvi operates — particularly around the authenticity of its marketing materials, the accuracy of its advertising claims, and whether customers are getting the transparency they deserve.
Before you sign up, here's what you need to know.
The Deepfake and Fake Testimonial Allegations
In May 2025, Futurism published an investigation that found multiple concerning practices on Medvi's website and in its advertising.
AI-generated patient photos. The investigation found that the "happy customer" images on Medvi's website appeared to be entirely AI-generated — synthetic images of people who do not exist, presented as real Medvi patients.
Deepfaked before-and-after photos. More seriously, the investigation traced Medvi's "patient success stories" to weight loss photos that had been circulating online for years — in some cases dating back to 2016 and 2017, before semaglutide was even approved for weight loss. The faces in the original photos appeared to have been altered using deepfake technology to disguise the real people and present them as Medvi customers.
One before-and-after attributed to a patient called "Michael P" was traced back to a 2018 Daily Mail article about people who lost weight after quitting drinking. The weight loss had nothing to do with GLP-1 medication.
Fake press logos. The website displayed logos from The New York Times, Bloomberg, Forbes, and other major publications, implying mainstream press coverage. The investigation found no evidence of coverage from most of these outlets.
AI-generated Ozempic ads. Medvi ran digital advertisements featuring AI-generated images of Ozempic boxes that looked nothing like the real product — covered in garbled text and misspelled brand names.
Regulatory and Compliance Concerns
Beyond the marketing issues, there are broader questions about the compounded GLP-1 market that apply to Medvi and similar companies.
The FDA declared the semaglutide shortage resolved in February 2025. The enforcement discretion period for 503A compounding pharmacies ended in April 2025, and for 503B outsourcing facilities in May 2025. This means compounding pharmacies can generally no longer produce copies of FDA-approved semaglutide products.
Many telehealth companies, including Medvi, have continued selling compounded versions by arguing their formulations are "not essentially copies" because they include additional ingredients. This legal argument is being actively litigated and the outcome remains uncertain.
Additionally, in December 2025, legislators sent letters to Meta citing Medvi ads that guaranteed "no side effects, just real results" — a claim that violates FDA rules for prescription drug advertising, which require disclosure of major side effects.
What Customers Report
Medvi holds approximately a 4-star rating on Trustpilot with over 11,000 reviews. Many customers report positive experiences with the medication itself, citing weight loss results, helpful providers, and convenient delivery.
However, negative reviews cite issues including being charged before physician consultation, receiving the wrong medication, contradictory cancellation instructions from different staff members, and difficulty reaching human support.
What to Look for in a Peptide or GLP-1 Telehealth Provider
If you're evaluating telehealth options for weight management or peptide therapy, here's what to check before signing up with any company:
Certificate of Analysis (COA). Does the company include a lab report verifying the purity and potency of your medication with every shipment? If they don't, you have no way to verify what's actually in the vial.
Real physician oversight. Is a licensed, board-certified physician reviewing your medical history before writing a prescription? Or are you just filling out a form and getting auto-approved?
Authentic testimonials. Are the patient photos and success stories real? Reverse image search any before-and-after photos. If they appear elsewhere online, that's a red flag.
Press claims. If a company displays media logos, click through and verify the coverage actually exists.
Transparent pricing. Are there hidden fees, mandatory minimums, or unclear refund policies?
Clear regulatory disclosures. Any legitimate telehealth company selling compounded medications should prominently disclose that these products are not FDA-approved and have not been evaluated for safety or effectiveness.
The Bottom Line
Medvi's core product — connecting patients with physicians who can prescribe GLP-1 medications — is a legitimate telehealth model used by many companies. The medications themselves can be effective for weight management when prescribed and monitored appropriately.
The concern isn't the service model. It's the marketing practices. Using deepfaked patient photos, AI-generated testimonials, fake press logos, and ads that promise "no side effects" crosses a line from aggressive marketing into deception. Customers deserve to make informed decisions based on real information, not synthetic content designed to manufacture trust.
If transparency, verified quality, and honest marketing matter to you, look for telehealth providers that include Certificates of Analysis, use real patient testimonials with proper consent, and make clear regulatory disclosures.
Pepta is a physician-prescribed peptide therapy platform that includes a Certificate of Analysis with every order, never uses AI-generated patient photos or fake testimonials, and provides transparent pricing with no contracts. [Learn more about our approach.]